Background/Aims: Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic patients. This study evaluated the efficacy and tolerability of peginterferon and ribavirin treatment in patients with hepatitis C virus (HCV)-related cirrhosis. Methods: Eighty-six patients with clinically diagnosed liver cirrhosis were treated with either peginterferon alpha-2a (n=51) or peginterferon alpha-2b (n=35) plus ribavirin. The sustained virologic response (SVR) and adverse effects were analyzed retrospectively. Results: Of the 86 patients (55 males), 48 patients (55.8%) had HCV genotype 1 infection and 38 (44.2%) had genotype non-1 infection. The overall SVR rate was 34.9% (30/86), and the rates of SVR in the genotype 1 and non-1 patients were 20.8% (10/48) and 52.6% (20/38), respectively. The multivariate analysis revealed that having HCV genotype 1 (P=0.003) and high baseline viral load (>8.0×10 5 IU/mL, P=0.012) were the independent predictive factors for SVR failure. In 20.9% (18/86) of the patients, treatment was not completed due to adverse events (27.8%), loss to follow-up (50.0%), and other reasons (22.2%). Conclusions: Peginterferon and ribavirin combination therapy was relatively effective and feasible for clinically diagnosed HCV patients, especially in those with genotype non-1 infection and low baseline viral load. (Korean J Hepatol 2011;17:220-225)
INTRODUCTION
Hepatitis C virus (HCV) infection may affect 2.5-3.0% of the world's population. 1 Among Koreans older than 40 years, 1.3%
are positive for HCV antibodies. 2 Liver cirrhosis may develop in 20% of those infected and 1-4% of the patients with cirrhosis may develop hepatocellular carcinoma (HCC) annually. 3 Combination therapy with pegylated-interferon (peginterferon) and ribavirin reduces the rate of progression of liver fibrosis in patients with chronic hepatitis C. 4 Interferon treatment for patients with HCV-related liver cirrhosis inhibits the development of HCC and it improves survival. 5 These results indicate that cirrhotic patients with chronic hepatitis C as well as patients with chronic hepatitis C should be treated to prevent progression of cirrhosis and the development of HCC. Combination therapy with peginterferon and ribavirin is the optimal treatment for patients with chronic HCV infection. 6 The sustained virologic response (SVR) rate for patients with HCV genotype 1 and HCV genotype 2 or 3, who received peginterferon alpha and ribavirin combination therapy was reported to be 42-46% and 76-80%, respectively. 7, 8 It was shown that the SVR rate for patients with uncomplicated, biopsy-proven HCV cirrhosis was 33-48%. 7, 9 However, there is little data on patients who have been diagnosed as having HCV cirrhosis by radiological evaluation and/or who have thrombocytopenia or esophageal and gastric varices seen on upper endoscopy.
The aim of this study was to evaluate the SVR rate, the completion rate of treatment, the causes of discontinuation of treatment and the adverse events in patients with clinically diagnosed liver cirrhosis and who received peginterferon and ribavirin combination therapy.
PATIENTS AND METHODS

Patients
We investigated the patients with HCV-related cirrhosis who 
Study design
The quantitative HCV-RNA was assessed using Amplicor Assessment of efficacy and the adverse events 
Statistical analysis
The data was analyzed by SPSS 13. 
RESULTS
Patient characteristics
A total of 86 patients were enrolled in this study. (Table 3) .
Tolerability and adverse events
Five patients stopped the treatment due to adverse events. The types of adverse events were thrombocytopenia (2 patients), depression (1 patient), anxiety disorder (1 patient) and cerebral vascular hemorrhage (1 patient). The other profiles of adverse events were "flu-like" symptoms, neutropenia, anemia, thrombocytopenia, depression, anorexia, fatigue, myalgia, headache, insomnia, nausea, weight loss, itching, alopecia and rash (Table 4 ). The peginterferon dose had to be reduced in 18 patients (20.9%) and the ribavirin dose had to be reduced in 21 
DISCUSSION
The SVR rate for patients with compensated, biopsy-proven HCV cirrhosis is 34-53%, which was lower than that of the chronic hepatitis patients without cirrhosis. [7] [8] 12 The SVR rate for HCV cirrhotic patients with portal hypertension is 21.6%. 13 In our study, the overall SVR rate of patients who were clinically diagnosed as cirrhosis was 34.9%. This was lower than that of the patients who were diagnosed as cirrhosis through liver biopsy in other studies, 14 but slightly higher than those of studies on patients with portal hypertension. Liver histological examination based on percutaneous needle biopsy is considered as a gold standard method for diagnosis of liver cirrhosis. However, liver
biopsy cannot be performed routinely at clinical practice because of complication risk and patients' discomforts. and have high viral load before the treatment. It has also been reported that these factors are associated with SVR in patients with compensated liver cirrhosis. 8, 18, 19 The present study also found that only these two factors were associated with SVR, which is consistent with the results of other studies.
In our study, there were 5 patients (5.8%, 5/86) who discontinued treatment due to adverse reactions of peginterferon and ribavirin combination therapy. This was similar to about 6.0-10.3%
reported in domestic studies on chronic hepatitis C patients, 16, 17 but lower than 16.0-32.3% reported in studies on patients who were accompanied by compensated liver cirrhosis or portal hypertension. 13, 14 However, simple comparison is not warranted because this was a retrospective study, and there is the possibility that some of the 9 patients (10.5%) who were not followed up without particular reason may voluntarily discontinued the treatment due to other side effects than hematological adverse reactions. Nevertheless, as treatment stopped in less than 20% of patients when these patients were included, the number of cases who stopped treatment due to adverse reactions of peginterferon and ribavirin combination therapy in patients with cirrhosis was similar to that of chronic hepatitis C patients. Of 86 patients, the patients who reduced peginterferon and ribavirin due to hematological adverse reactions were 20.9% (18/86) and 24.4%
(21/86), respectively. These rates of dose reduction were not significantly greater in patients with portal hypertension, although hematologic adverse reaction expected to be more frequent.
As the limitation of retrospective study, we could not follow up every patients who had started the treatment to the completion of treatment, and the medical records were not standardized and consistent by organization. Therefore, so it is difficult to arrive at final conclusions. However, even schematically, this study confirmed the expected results and possible adverse reactions of the peginterferon and ribavirin combination therapy in chronic hepatitis C patients who were clinically diagnosed with cirrhosis.
In conclusion, the overall SVR can be achieved in one-third of clinically diagnosed cirrhosis patients with HCV infection.
Especially for patients with genotype non-1 infection, the SVR rate was high. Therefore, planning treatment on the basis of viral genotype and baseline viral load are needed to select patients who are more likely to achieve SVR.
